For laboratory studies, it was reported that addition of Aidi injection to chemotherapy could significantly increase tumor inhibition rate and reduce Her-2/neu expression level in the nude mice breast carcinoma implanted of Her-2/neu over expression [46]; it could significantly inhibit cancer cell proliferation, induce cell apoptosis, and reduce cell diameter in the ErbB2 positive breast cancer cell BT-474, SK-BR-3, and HCC-1954 [47]; it significantly inhibited proliferation of MCF-9 cells in dose-dependent manner, accompanying altered expression profiles of microRNAs in MCF-9 cells [48]. Here, ERBB2 is linked to hepatocellular carcinoma.